ODAC To Evaluate Strength Of Objective Response Rate Of Arzerra In CLL
This article was originally published in The Pink Sheet Daily
Executive Summary
Meeting at the ASCO annual meeting, FDA’s oncology panel will consider whether the effect sizes of surrogate endpoints observed in patients refractory to two drugs justify accelerated approval of GSK/Genmab’s ofatumumab.
You may also be interested in...
Murky Response Measures Shouldn’t Block Accelerated Approval Of GSK’s Arzerra, ODAC Says
Meeting at the ASCO annual meeting, the panel votes 10-3 that an ORR of 42 percent is likely to predict clinical benefit in chronic lymphocytic leukemia patients refractory to two drugs.
Murky Response Measures Shouldn’t Block Accelerated Approval Of GSK’s Arzerra, ODAC Says
Meeting at the ASCO annual meeting, the panel votes 10-3 that an ORR of 42 percent is likely to predict clinical benefit in chronic lymphocytic leukemia patients refractory to two drugs.
Genmab, GSK On Track To File Ofatumumab For CLL In Late 2008
Positive top-line Phase III results show response rates as high as 51 percent.